Klingemann H G, Brunswig D, Liehr H
Z Gastroenterol. 1978 Sep;16(9):564-73.
The question is still open, whether a pathologic formation of fibrinogen or an insufficient stabilized fibrin are causative factors within the complex disorders in hemostasis in patients with liver cirrhosis. Thus, 45 patients with liver cirrhosis, which was proven by liver biopsy, were investigated by means of sodium-dodecyl-sulfate (SDS) polyacrylamidgel-electrophoresis in order to evaluate, whether the liver produces a pathological fibrinogen or whether the formation of fibrin from fibrinogen is defect. The fibrin stabilizing factor (factor XIII) was measured by immunological methods. In order to have a mean of the stage of the disease, 37 patients were subdivided by the extend or their porto-caval collateral circulation and further 8 patients were investigated having bleeding from esophageal varices. By the results evidence accrued that in advanced stages of liver cirrhosis and a marked porto-caval collateral circulation polymerization of fibrinogen was insufficiently, especially, the formation of alpha-chains was altered, whereas the formation of gamma-dimers, the separation of fibrinopeptides from fibrinogen, and the aggregation of fibrinmonomers were normal. This defect in fibrin structure was positive correlated with the stage of liver cirrhosis, which correlated negative with the plasma activity of factor XIII. In vitro, the defect in fibrin formation, from fibrinogen was abolished by adding factor XIII to the assay. Thus, in liver cirrhosis fibrin formation is altered because of factor XIII deficiency, but a normal fibrinogen is synthesized by the liver. In consequence, the administration of factor XIII preparations is suggested as one clinical action among others to benefit the hemostatic disorders, especially in patients with bleeding from esophageal varices.
肝硬化患者止血功能复杂紊乱的病因中,纤维蛋白原的病理性形成或纤维蛋白稳定性不足是否为致病因素,这一问题仍未明确。因此,对45例经肝活检证实为肝硬化的患者进行了研究,采用十二烷基硫酸钠(SDS)聚丙烯酰胺凝胶电泳来评估肝脏是否产生病理性纤维蛋白原,或者纤维蛋白原形成纤维蛋白的过程是否存在缺陷。通过免疫学方法测定纤维蛋白稳定因子(因子 XIII)。为了对疾病阶段有一个平均值,37例患者根据门腔静脉侧支循环的范围进行了细分,另外8例有食管静脉曲张出血的患者也进行了研究。结果表明,在肝硬化晚期且门腔静脉侧支循环明显时,纤维蛋白原的聚合不足,尤其是α链的形成发生了改变,而γ二聚体的形成、纤维蛋白原中纤维蛋白肽的分离以及纤维蛋白单体的聚集均正常。纤维蛋白结构的这种缺陷与肝硬化阶段呈正相关,而与因子 XIII 的血浆活性呈负相关。在体外,通过在测定中加入因子 XIII,可消除纤维蛋白原形成纤维蛋白的缺陷。因此,在肝硬化中,由于因子 XIII 缺乏,纤维蛋白形成发生改变,但肝脏合成的纤维蛋白原是正常的。因此,建议使用因子 XIII 制剂作为一种临床措施,以改善止血功能紊乱,特别是对于有食管静脉曲张出血的患者。